Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.46 |
| ▸ | PDE3B known ✓ | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.42 |
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.41 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 2/20 | 0.65 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | APAF1 | O14727 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17975809 | 0.93 | TERT (0.74) | TERTAPPAPAF1MAPTPOLB | |
| Hydrochloric Acid SCHEMBL28730611 | 0.87 | TERT (0.67) | TERTMAPTPOLBBLMTHRB | |
| Hydrochloric Acid SCHEMBL2478442 | 0.87 | APP (0.71) | TERTAPPAPAF1MAPTPOLB | |
| SCHEMBL5696512 | 0.84 | APP (0.74) | TERTAPPAPAF1MAPTPOLB | |
| SCHEMBL11443324 | 0.84 | APP (0.74) | TERTAPPAPAF1MAPTPOLB | |
| Hydrochloric Acid SCHEMBL11311746 | 0.81 | TERT (0.96) | TERTAPPMAPTPOLBBLM | |
| SCHEMBL9754585 | 0.79 | TERT (1.00) | TERTAPPMAPTPOLBBLM | |
| SCHEMBL15423130 | 0.77 | TERT (0.74) | TERTAPPMAPTPOLBBLM | |
| SCHEMBL9066719 | 0.77 | TERT (0.57) | TERTAPPMAPTTHRBMEN1 | |
| Hydrochloric Acid SCHEMBL11146532 | 0.76 | APAF1 (0.65) | TERTAPPAPAF1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4327874-A2 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WisTa Laboratories Ltd. (SG) | 2024-02-28 | — | — | EP | disclosed |
| EP-3689346-B1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS FOR TREATING TAUOPATHIES | WISTA LAB LTD (SG) | 2024-01-24 | — | — | EP | disclosed |
| EP-3689346-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WisTa Laboratories Ltd. (SG) | 2020-08-05 | — | — | EP | disclosed |
| EP-3112358-B1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WISTA LAB LTD (SG) | 2020-04-29 | — | — | EP | disclosed |
| US-10399955-B2 | 3,6-disubstituted xanthylium salts | WISTA LABORATORIES LTD. (SG) | 2019-09-03 | — | — | US | disclosed |
| US-20170088534-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WISTA LABORATORIES LTD. (SG) | 2017-03-30 | — | — | US | disclosed |
| US-9549933-B2 | 3,6-disubstituted xanthylium salts | WISTA LABORATORIES LTD. (SG) | 2017-01-24 | — | — | US | disclosed |
| EP-3112358-A2 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WisTa Laboratories Ltd. (SG) | 2017-01-04 | — | — | EP | disclosed |
| EP-2373660-B1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS AS MEDICAMENTS | WISTA LAB LTD (SG) | 2016-08-17 | — | — | EP | disclosed |
| US-20140161731-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WISTA LABORATORIES LTD. (SG) | 2014-06-12 | — | — | US | disclosed |
| US-8658665-B2 | 3,6-disubstituted xanthylium salts and use thereof in treatment of tauopathies | WISTA LABORATORIES LTD. (SG) | 2014-02-25 | — | — | US | disclosed |
| US-20110300074-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | WISTA LABORATORIES LTD. (SG) | 2011-12-08 | — | — | US | disclosed |
| EP-2373660-A2 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS AS MEDICAMENTS | Wista Laboratories Ltd. (SG) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010067078-A2 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS AS MEDICAMENTS | WISTA LABORATORIES LTD. (SG) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140161731-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | MAPT, PSEN2, PSEN1 | GAA 385/4885PDE3B 3290/4885PDE3A 2714/4885 |
| US-10399955-B2 | 3,6-disubstituted xanthylium salts | MAPT, PSEN2, PSEN1 | GAA 385/4885PDE3B 3290/4885PDE3A 2714/4885 |
| US-20170088534-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | MAPT, PSEN2, PSEN1 | GAA 385/4885PDE3B 3290/4885PDE3A 2714/4885 |
| US-20110300074-A1 | 3,6-DISUBSTITUTED XANTHYLIUM SALTS | MAPT, PSEN2, PSEN1 | GAA 77/4885PDE3B 1322/4885PDE3A 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.